27 August 2021 : Clinical Research
A Prognostic Model of Gastrointestinal Diffuse Large B Cell Lymphoma
Fan Gao1ACDEF, Zhan-fang Wang2BCD, Lei Tian1DF, Fei Dong1BC, Jing Wang1BD, Hong-mei Jing1BD, Xiao-yan Ke1AG*DOI: 10.12659/MSM.929898
Med Sci Monit 2021; 27:e929898
Table 1 Patient information and 3-year survival rate.
| Clinical features | Number and proportion of patients | Number and proportion of patients that survived | χ2 | p-value |
|---|---|---|---|---|
| Total | 82 | 48 (58.5%) | ||
| Age (years) | ||||
| ≤60 | 33 (40.2%) | 24 (72.7%) | 9.0162 | 0.01102 |
| Between 60–75 | 34 (41.5%) | 20 (58.5%) | ||
| >75 | 15 (18.3%) | 4 (26.6%) | ||
| Gender | ||||
| Male | 45 (54.9%) | 27 (60.0%) | 0.0051 | 0.9431 |
| Famale | 37 (45.1%) | 21 (56.8%) | ||
| PGL | ||||
| Yes | 38 (46.3%) | 28 (73.6%) | 5.5823 | 0.01814 |
| No | 44 (53.7%) | 20 (45.5%) | ||
| Region involved | ||||
| Stomach | 42 (51.2%) | 28 (66.7%) | 0.2002 | |
| Small intestine | 12 (14.6%) | 4 (33.3%) | ||
| Ileocecum | 14 (17.1%) | 8 (57.1%) | ||
| Colon | 4 (4.9%) | 1 (25.0%) | ||
| Rectum | 1 (1.2%) | 1 (100%) | ||
| Multiple sites | 9 (11.0%) | 6 (66.7%) | ||
| Symptoms | ||||
| Asymptomatic | 6 (7.3%) | 3 (50.0%) | 0.7485 | |
| Non-specific symptoms | 58 (70.7%) | 33 (56.9%) | ||
| Specific symptoms | 18 (22.0%) | 12 (66.7%) | ||
| Pre-treatment complications | ||||
| Yes | 33 (40.2%) | 17 (51.5%) | 0.68985 | 0.4062 |
| Bleeding | 20 (24.4%) | 12 (60.0%) | ||
| Perforation | 0 (0.0%) | 0 (0.0%) | ||
| Obstruction | 13 (15.9%) | 4 (30.8%) | ||
| Intussusception | 5 (0.06%) | 3 (60.0%) | ||
| No | 49 (59.8%) | 31 (63.2%) | ||
| Post-treatment complications | ||||
| Yes | 14 (17.1%) | 4 (28.6%) | 4.8455 | 0.02772 |
| No | 68 (82.9%) | 44 (64.7%) | ||
| Pathological subtype | ||||
| ABC | 38 (46.3%) | 21 (55.3%) | 0.34074 | 0.8434 |
| GCB | 24 (29.3%) | 15 (62.5%) | ||
| Not classified | 20 (24.4%) | 12 (60.0%) | ||
| Bcl2 | ||||
| Positive | 30 (36.6%) | 12 (40.0%) | 2.9881 | 0.08388 |
| Negative | 22 (26.8%) | 15 (68.2%) | ||
| Bcl6 | ||||
| Positive | 34 (41.5%) | 21 (61.8%) | 0.53684 | 0.4637 |
| Negative | 34 (41.5%) | 17 (50.0%) | ||
| Ann Arbor stage | ||||
| I | 17 (20.7%) | 14 (82.4%) | 0.04476 | |
| II | 14 (17.1%) | 10 (71.4%) | ||
| III | 9 (11.0%) | 5 (55.6%) | ||
| IV | 42 (51.2%) | 19 (45.2%) | ||
| IPI score | ||||
| 0 | 9 (11.1%) | 8 (88.9%) | 0.01874 | |
| 1 | 13 (15.9%) | 8 (61.5%) | ||
| 2 | 17 (20.7%) | 13 (76.4%) | ||
| 3 | 15 (18.3%) | 6 (40.0%) | ||
| 4 | 20 (24.4%) | 8 (40.0%) | ||
| 5 | 2 (2.4%) | 0 (0.0%) | ||
| Types of ulcers | ||||
| No ulcer | 22 (26.8%) | 9 (40.9%) | 0.02365 | |
| Simple ulcer | 30 (36.6%) | 24 (80.0%) | ||
| Multiple ulcers | 12 (14.6%) | 6 (50.0%) | ||
| Giant Ulcer | 13 (15.9%) | 7 (53.8%) | ||
| Endoscopic findings | ||||
| Mucosal erythema/benign-appearing gastric ulcer | 48 (58.5%) | 31 (64.6%) | 1.5733 | 0.4554 |
| Thickened or diffuse bulge | 15 (18.3%) | 7 (46.7%) | ||
| Mass | 14 (%) | 8 (57.1%) | ||
| PGL – primary gastrointestinal lymphoma; specific symptoms include hematemesis, blood in the stool, melena, and cessation of exhaustion; ABC – activated B cell type; GCB – germinal center B cell type. | ||||